Search Weight Loss Topics:

Page 87«..1020..86878889..100..»

Nov 16

Why men who compete as female will always have an unfair advantage over real women – Lifesite

November 15, 2019 (WORLD Magazine) Activists appear to have two approaches to controlling the narrative concerning transgender athletes' successes in women's sports: Attack the critics, or keep things hush-hush.

Neither has proven particularly effective at quelling a controversy that needn't exist, isn't going away, and really has only one solution.

Rachel (formerly Rhys) McKinnon went on the offensive after defending his 200-meter sprint title in the women's 3539 age group at the Masters Track Cycling Championships in Manchester, England, in late October. After setting a world record during qualifying, McKinnon won the race for the second straight year by four-tenths of a second, or roughly 15 meters in a race typically decided by centimeters.

In the wake of victory, McKinnon blasted those who decry the unfairness of biological males defeating women: "I have yet to meet a real champion who wants trans women banned," the 37-year-old Canadian said. "If you win because bigotry got your competition banned ... you're a loser."

Meanwhile, publicity handlers tried in vain to keep June (formerly Jonathan) Eastwood's transgender status quiet after the Big Sky Conference named the University of Montana cross-country runner its Female Athlete of the Week in late October. Eastwood received the honor after placing second in the women's race at Santa Clara University's Bronco Invitational in Sunnyvale, Calif.

In touting Eastwood's accolade, both the Big Sky and Montana websites failed to mention that Eastwood had competed as a male with moderate success as recently as last year. Eastwood's bio on the Montana women's cross-country website omits the senior's prior running experience entirely.

Something similar happened with CeCe (formerly Craig) Telfer of New Hampshire's Franklin Pierce University afterhe wonthe NCAA Division II title in the women's 400-meter hurdles last spring. And yet, Eastwood's transgender status, like Telfer's, still surfaced not least becauseThe Missoulian, the newspaper that covers Montana athletics in the university's home city of Missoula, ran a preseason profile hailing Eastwood's history-making turn as the NCAA's first openly transgender cross-country runner.

While Union Cycliste Internationale, cycling's international governing body, has a testosterone threshold that biological males cannot exceed if they wish to compete as women, the NCAA has none: The governing body for major-college sports simply requires biologically male athletes to take testosterone-suppressing hormones for at least one year. McKinnon and Eastwood have apparently done enough to comply with the rules of their sports' respective governing bodies.

Still, science is proving that even after taking testosterone-suppressing hormones, biologically male athletes retain competitive advantages over women:The Journal of Medical Ethicspublished a study in August stating that biological males do not lose significant muscle mass or power after suppressing their testosterone levels below International Olympic Committeestandards. The study also found that biological males who suppress their testosterone levels can retain and rebuild their muscle mass, power, and strength through training.

Some, like McKinnon, say transgender athletes should be able to compete according to their gender identity and without suppressing their testosterone levels. They might counter any arguments about unfairness by pointing to Eastwood's performance at the Big Sky cross-country championships on Nov. 2: He placed eighth proof that biological males are not automatically better than biological women in head-to-head competition.

However, Eastwood never placed higher than 24that a Big Sky championship meet when running against men. In other words, even if he wasn't faster than every woman who competed on Nov. 2, he was still faster than most and he displaced one from earning all-conference honors.

In light of the study's findings, the only real way to ensure competitive fairness in women's sports is to keep men out.

Published with permission from WORLD Magazine.

Continued here:
Why men who compete as female will always have an unfair advantage over real women - Lifesite

Nov 16

Ford v Ferrari: A Rollicking Tale of Fast Cars and Capitalism – The Atlantic

The film follows Carroll Shelby (played by Matt Damon), a retired driver turned engineer who is contracted by the execs Henry Ford II (Tracy Letts) and Lee Iacocca (Jon Bernthal) to build out Fords racing division. Shelby brings aboard Ken Miles (Christian Bale), a stubborn Brit with a colossal chip on his shoulder and an attitude far from the anodyne politeness thats expected at Ford. Much of the movies two-and-a-half-hour running time revolves around Shelbys corporate battles to convince his bosses that Miles belongs in the drivers seat. But the heart of the film is in the oily garages below the executive suites, where Fords mechanics and drivers strive to create a machine worthy of challenging Ferraris perfection.

Whenever Mangold and his cinematographer Phedon Papamichael are shooting racing footage, Ford v Ferrari practically vibrates off the screen. Car racing in the 1960s was still intense and raw (the technology behind functioning brakes was primitive at best), and Mangold works to convey just how death-defying and brutal the day-long Le Mans race was for a driver. Fords offices, meanwhile, are burnished and beautiful tableaus of mid-century modernity, expensive-looking exhibitions of American wealth that are just as crucial to the companys image as the factory floor. Letts gives a quietly nasty performance as Ford II, emphasizing the CEOs vanity and churlishness as much as the resources at his disposal.

The biggest conflict in Ford v Ferrari isnt the automakers contest, but Shelby and Miless struggle to maintain their integrity while pleasing their corporate overlords. Amid all the testosterone, characters like Mollie Miles (Caitriona Balfe), Kens wife, have few opportunities to shine. Though the script (by Jason Keller and Jez and John-Henry Butterworth) tries to give Balfe a few scenes that assert her personality, shes largely confined to the stock role of frustrated but supportive partner. Noah Jupe, who plays Ken and Mollies plucky son, Peter, gets similarly lost.

Still, the climax of the film, which details all the unpredictable twists of the race itself, brings home the themes Mangold has been working to flesh out. Ford v Ferrari couldve been an easy tale of a dark horse winning against a runaway sporting favorite, but the reality of the 1966 Le Mans contest was much stranger. The movie rejects hackneyed storytelling tropes to depict the limits of ingenuity in the face of capitalistic might, and the result is a rich crowd-pleaser with a pessimistic edge.

We want to hear what you think about this article. Submit a letter to the editor or write to

See the original post:
Ford v Ferrari: A Rollicking Tale of Fast Cars and Capitalism - The Atlantic

Nov 13

Testosterone therapy prescription linked to increased VTE risk in JAMA study – Specialty Medical Dialogues

The researchers conducted the study to evaluate whether the clinical prescription of testosterone therapy was associated with short-term risk of venous thromboembolism in men with and without hypogonadism or not. They found that Testosterone therapy is associated with increased risk for venous thromboembolism (VTE) in men. The case-crossover study has been published in JAMA Internal Medicine.

According to the American Heart Association, Venous thromboembolism (VTE) refers to a blood clot that starts in a vein. It is the third leading vascular diagnosis after a heart attack and stroke and includes Deep vein thrombosis andPulmonary embolism .

The researchers used insurance claims databases, researchers identified roughly 40,000 men without cancer whod experienced a VTE. Out of them, nearly 8% were diagnosed with hypogonadism. Each patient served as his own control. The immediate 6 months before the VTE was the case period, and the 6 months before that was the control period.

................................ Advertisement ................................

A claim for testosterone therapy was more common in the 6 months before VTE, compared with the control period, both for men without hypogonadism (0.8% for case period vs. 0.5% for control period) and for those with (34% vs. 22%).

It was found that the use of testosterone therapy in the 6-month case period was associated with an increased risk of venous thromboembolism among men with and without hypogonadism. The testosterone prescription during the case period was associated with roughly double the risk for VTE. The risk was highest in the first 3 months of starting testosterone.

................................ Advertisement ................................

The authors concluded that testosterone therapy was associated with an increase in short-term risk for VTE among men with and without hypogonadism, with some evidence that the association was more pronounced among younger men. These findings suggest that caution should be used when prescribing testosterone therapy.

For further reference log on to:

JAMA Intern Med.Published online November 11, 2019. doi:

Testosterone therapy prescription linked to increased VTE risk in JAMA study - Specialty Medical Dialogues

Nov 13

Value and Size Of Testosterone Replacement Therapy Market From 2019 To 2024: Detailed Research Report – The Denton Chronicle

Testosterone Replacement Therapy Market to 2024: Deep Analysis

The report offers a complete research study of the globalTestosterone Replacement Therapy Marketthat includes accurate forecasts and analysis at global, regional, and country levels. It provides a comprehensive view of the global Testosterone Replacement Therapy market and detailed value chain analysis to help players to closely understand important changes in business activities observed across the industry. It also offers a deep segmental analysis of the global Testosterone Replacement Therapy market where key product and application segments are shed light upon. Readers are provided with actual market figures related to the size of the global Testosterone Replacement Therapy market in terms of value and volume for the forecast period 2019-2024.

The following Companies as theKey playersin the Global Testosterone Replacement Therapy Market Research Report are AbbVie, Endo International, Eli lilly, Pfizer, Actavis (Allergan), Bayer, Novartis, Teva, Mylan, Upsher-Smith, Ferring Pharmaceuticals, Kyowa Kirin, Acerus Pharmaceuticals.

Free Sample Report + All Related Graphs & Charts @

Market Overview of Global Testosterone Replacement Therapy

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split intoGels, Injections, Patches.

On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including Hospitals, Clinics.

Geographically, The Testosterone Replacement Therapy market report studies the top producers and consumers, focuses on product capacity, production, value, consumption, market share and growth opportunity in these key regions, covering:North America, Europe, China, Japan and others.

Grab Your Report at an Impressive Discount (Use Corporate email ID to Get Higher Priority) @

Furthermore, Global Testosterone Replacement Therapy Market following points are involved along with a detailed study of each point:

Major Players:The report provides company profiling for a decent number of leading players of the global Testosterone Replacement Therapy market. It brings to light their current and future market growth taking into consideration their price, gross margin, revenue, production, areas served, production sites, and other factors.

Testosterone Replacement Therapy Market Dynamics:The report shares important information on influence factors, market drivers, challenges, opportunities, and market trends as part of market dynamics.

Global Testosterone Replacement Therapy Market Forecast:Readers are provided with production and revenue forecasts for the global Testosterone Replacement Therapy market, production and consumption forecasts for regional markets, production, revenue, and price forecasts for the global Testosterone Replacement Therapy market by type, and consumption forecast for the global Testosterone Replacement Therapy market by application.

Regional Market Analysis:It could be divided into two different sections: one for regional production analysis and the other for regional consumption analysis. Here, the analysts share gross margin, price, revenue, production, CAGR, and other factors that indicate the growth of all regional markets studied in the report.

Testosterone Replacement Therapy Market Competition:In this section, the report provides information on Competitive situations and trends including merger and acquisition and expansion, market shares of the top three or five players, and market concentration rate. Readers could also be provided with production, revenue, and average price shares by manufacturers.

Get Customized Report in your Inbox within 24 hours at:

Significant Facts around Testosterone Replacement Therapy Market Report:

This study uncovers Testosterone Replacement Therapy business summary, item impression, market analysis, distribution networks breakdown, demand, and supply proportion and import/export subtleties. The Industry report highlights distinctive methodologies and methodology supported by the Testosterone Replacement Therapy market key players to settle on imperative business choices. Testosterone Replacement Therapy market describes few parameters, for example, production assessment, Testosterone Replacement Therapy marketing strategies, Distributors/Traders and impact factors are additionally referenced in this Testosterone Replacement Therapy research report.

Browse the full report Description, TOC and Table of Figure @

Customization Available

With the given market data, Researchers offer customization according to the companys specific needs. The following customization options are available for the report:

Regional and country-level analysis of the Testosterone Replacement Therapy market, by end-use.

Detailed analysis and profiles of additional market players.

Value and Size Of Testosterone Replacement Therapy Market From 2019 To 2024: Detailed Research Report - The Denton Chronicle

Nov 13

New book refutes ‘boys will be boys’ – Futurity: Research News

Share this Article

You are free to share this article under the Attribution 4.0 International license.

A new book traces the origins of the claim that boys will be boysand refutes it.

Thirty years ago, in downtown Mexico City, Matthew Gutmann took a picture of a man holding a baby. Little did he know then that photo would launch a decades-long career studying men and masculinity around the world.

I showed that photo to a bunch of people in the United States, and I kept getting vehement reactions, says Gutmann, a professor of anthropology at Brown University.

People said, This is unreal. This is an aberration. I tried to explain to an art editor at a university press that the photo was candid and not posed, and he says, Thats impossible. Mexican men are machos; they dont carry babies.'

For Gutmann, that moment launched a quest to learn more about men and masculinity in Mexico. He has since studied the state of sexual and reproductive health across Latin America, investigated the concept of masculine loyalty among American veterans who fought in Iraq, and observed changes in workplace gender standards in urban China, where he currently teaches as a visiting professor.

In some ways, the book Are Men Animals? (Basic Books, 2019) is a distillation of all that Gutmann has learned since he took that fateful photo as a graduate student. His book takes the reader on a world tour, examining the women-only subway cars of Mexico City, the barrio of Santo Domingo and the so-called marriage market in Shanghai to demonstrate that theres no single definition of masculinity or manliness.

Ultimately, Gutmann says, he hopes Are Men Animals? emphasizes that men are more than testosterone and Y chromosomesthat theyre made as much by society as by biology.

The great feminist Simone de Beauvoir once wrote about women, Their biology is not their destiny,' Gutmann says. I think we need to say something similar about men. Mens biology is not their destiny, either.

Ahead of the release of Are Men Animals?, Gutmann answered a few questions about the book, his research, and the future of masculinity:

Original Study

Excerpt from:
New book refutes 'boys will be boys' - Futurity: Research News

Nov 13

Testosterone Replacement Therapy Market 2019| Recent Trends, In-depth Analysis, Market Size Research Report Forecast up to 2026 | Research Industry US…

Global Testosterone Replacement Therapy market report is the first of its kind research report that covers the overview, market dynamics, competitive analysis, and leading players numerous strategies to sustain in the global market. This report covers five top regions of the world and countries within, which shows the status of regional development, consisting of volume, size, market value, and price data.

The report takes a dashboard view of an entire Testosterone Replacement Therapy market by comprehensively analyzing market circumstance and situation and the various activities of leading players in the market such as mergers, partnerships, and acquisitions. This unique report explains the present industry situations that give the crystal-clear picture of the global Testosterone Replacement Therapy market to the clients.

Request For Sample PDF Report (Kindly Use Your Bussiness/Corporate Email Id to Get Priority):

Market Segmentation

Key players considered in the report include

AbbVieEndo InternationalEli lillyPfizerActavis (Allergan)BayerNovartisTevaMylanUpsher-SmithFerring PharmaceuticalsKyowa KirinAcerus Pharmaceuticals

On the basis of types, the global Testosterone Replacement Therapy market is primarily split into


Based on application, the global Testosterone Replacement Therapy market is primarily split into


Some of the significant factors such as marketing strategy, factor analysis, cost analysis, industrial chain, distributors and sourcing strategy are included in this report which makes it an exclusive one. The report on the global Testosterone Replacement Therapy market report is compiled by industry experts and properly examined which will highlight the key information required by the clients.

Regional Analysis

A unit of the report has given comprehensive information about regional analysis. It provides a market outlook and sets the forecast within the context of the overall global Testosterone Replacement Therapy market. Research Industry US has segmented the global Testosterone Replacement Therapy market into major geographical regions such as North America, Europe, Asia Pacific, South America, and the Middle East and Africa (MEA). Potential new entrants wishing to target only high growth areas are also included in this informative section of the global Testosterone Replacement Therapy market.

Based on geography, the global Testosterone Replacement Therapy market is divided into North America, Europe, Asia-Pacific, South America, and The Middle East & Africa. North America is further divided in the U.S., Canada, and Mexico, whereas Europe consists of the UK, Germany, France, Italy, and Rest of Europe. India, China, Japan, South Korea, and Rest of Asia-Pacific are the categorization of the Asia-Pacific region. The South America region includes Brazil, Argentina, and the Rest of South America, while The Middle East & Africa is categorized into GCC Countries, Egypt, South Africa, and the Rest of the Middle East & Africa.

Enquire Here For Queries Or Report Customization:

Following queries are answered in the Testosterone Replacement Therapy report:-

Get In Touch!

Navale ICON IT Park,

Office No. 407, 4th Floor, Mumbai Banglore Highway, Narhe, Pune

Maharashtra 411041

phone +91-020-67320403

Email [emailprotected]

Research Industry

Research Industry USA is a market research and consultative company that provides market research reports and business insights to large and small & medium enterprises. The company supports its clients to conceive business policies and accomplish sustainable growth in their particular market domain. We meet clients objectives, commitment and dedication on high standard and targeting possible prospects for market research reports.

Follow this link:
Testosterone Replacement Therapy Market 2019| Recent Trends, In-depth Analysis, Market Size Research Report Forecast up to 2026 | Research Industry US...

Nov 13

Testosterone Replacement Therapy Industry: Time to Invest in emerging Markets | Endo International, Pfizer, Novartis – News Description

AMA recently published a detailed study of over 180+ pages in its repository on Testosterone Replacement Therapy market covering interesting aspects of market with supporting development scenario till 2025. The study provides market size break-up by revenue and volume* for emerging countries and important business segments along with commentary on trending factors, growth drivers. Profiled players in study from the coverage used under bottom-up approach are AbbVie Inc. (United States), Endo International (Ireland), Eli Lilly and Company (United States), Pfizer (United States), Bayer (Germany), Actavis (Allergan) (United States), Novartis (Switzerland), Teva (Israel), Ferring Pharmaceuticals (Switzerland), Kyowa Kirin (Japan), Mylan (United States)

Next step one should take to boost sales? Track latest strategic steps and current scenario analysis of the market @

Testosterone is responsible for the development of male sexual characteristics and this hormone formed by the testicles. Insufficient production of testosterone causes erectile dysfunction. Testosterone Replacement Therapy (TRT) is generally termed as hormone therapy for men, designed to counteract the effects of reduced activity in the gonads or hypogonadism. Hypogonadism in men is clinical syndrome, which results in the failure of the testes to produce physiological levels of testosterone. Erectile dysfunction arises due to reduce testosterone production to overcome this testosterone replacement therapy is used to improve the problem.

Market Segmentationby Type (Creams or Gels, Patches, Injections, Buccal Adhesives, Implants, Oral), Application (Hospitals, Clinics)

Make an enquiry before buying this Report @

Whats Trending in Market: Increasing awareness about testosterone substitute therapy

Growth Drivers: Increasing prevalence of hypogonadism in adult men

The need for having an offspring amongst men

Restraints: High possibility of side effects related to testosterone replacement therapy

View Detailed Table of Content @

Country level Break-up includes:North America (United States, Canada and Mexico)Europe (Germany, France, United Kingdom, Spain, Italy, Netherlands, Switzerland, Nordic, Others)Asia-Pacific (Japan, China, Australia, India, Taiwan, South Korea, Middle East & Africa, Others)

Try a limited scope research document specific to Country or Regional matching your objective.

GET FULL COPY OF United States Testosterone Replacement Therapy market study @ USD 2000

And, Europe Testosterone Replacement Therapy market study @ USD 2500 Major Highlights of TOC:

Chapter One: Market Overview

Scope/Objective of the Study

Chapter Two: Executive Summary - Free of Cost

Chapter Three: Market Dynamics USD400

Market Drivers, Market Challenges, Market Trends

Chapter Four: Market Factor Analysis USD400

Supply/Value Chain Analysis, Porters Five Forces, PESTEL analysis, Market Entropy, Patent & Trademark Analysis, Market Development Scenario

Chapter Five and Seven: Global Testosterone Replacement Therapy, by Market Segmentation and Region (value, volume**) (2013-2024) USD2400

Global Testosterone Replacement Therapy

By Type (Creams or Gels, Patches, Injections, Buccal Adhesives, Implants, Oral)

By Application (Hospitals, Clinics)

Global Testosterone Replacement Therapy Region

North America (United States, Canada and Mexico)

Europe (Germany, France, United Kingdom, Spain, Italy, Netherlands, Switzerland, Nordic, Others)

Asia-Pacific (Japan, China, Australia, India, Taiwan, South Korea, Middle East & Africa, Others)

Chapter Six: Global Testosterone Replacement Therapy Manufacturers/Players Analysis USD1200

Competitive Landscape (Direct & Indirect Competitors), Market Share Analysis, Peer Group Analysis (2018), BCG Matrix, Company Profile, Downstream Buyers & Upstream Suppliers


Chapter Nine: Methodology/Research Approach, Data Source, Disclaimer

** If applicable

* Customized Section/Chapter wise Reports or Regional or Country wise Chapters are also available.

Buy this report @

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Contact Us: CRAIG FRANCIS (PR & Marketing Manager)[emailprotected]Ph: +1 (206) 317 1218

See more here:
Testosterone Replacement Therapy Industry: Time to Invest in emerging Markets | Endo International, Pfizer, Novartis - News Description

Nov 13

Nike will look into runner Mary Cain’s allegations of abuse – The Associated Press

Nike will look into runner Mary Cains allegations of abuse while she was part of Alberto Salazars training group. The runner says it reached the point where she started having suicidal thoughts and cutting herself.

Cain joined the disbanded Nike Oregon Project run by Salazar in 2013, soon after competing in the 1,500-meter final at track and fields world championships when she was 17.

Now 23, Cain told The New York Times in a video essay that she joined Nike because she wanted to be the best female athlete ever.

Instead, I was emotionally and physically abused by a system designed by Alberto and endorsed by Nike, she said.

Nike said in a statement these are deeply troubling allegations which have not been raised by Mary or her parents before. Mary was seeking to rejoin the Oregon Project and Albertos team as recently as April of this year and had not raised these concerns as part of that process.

The sportswear giant added it will take the allegations extremely seriously and will launch an immediate investigation to hear from former Oregon Project athletes.

Cain alleged that under Salazars direction she was told to lose weight and he created an arbitrary number of 114 pounds.

He would usually weigh me in front of my teammates and publicly shame me if I wasnt hitting weight, she said.

In 2015, Cain said after a race she told Salazar and the teams sports psychologist she was cutting herself and they pretty much told me they wanted to go to bed. I think for me that was my kick in the head, where I was like, This is a sick system.

Salazar was banned from the sport for four years by the U.S. Anti-Doping Agency for experiments with supplements and testosterone that were bankrolled and supported by Nike, along with possessing and trafficking testosterone. Nike shut down Salazars elite program. In addition, Nike said last month that longtime CEO Mark Parker would leave early next year.

Cain said that young girls bodies are being ruined by an emotionally and physically abusive system. Thats what needs to change.

In trying to cut weight, Cain said she didnt have her period for three years and broke five different bones. Cain also said Salazar wanted to give her birth control pills and diuretics to lose weight, the latter of which isnt allowed in track and field.

I ran terrible during this time, she added in the video. It reached a point where I was on the starting line, and Id lost the race before I started because in my head all I was thinking of was not the time I was trying to hit but the number on the scale I saw earlier that day.

Cain drew overwhelming support from the running community. Shalane Flanagan reached out to her on Twitter, posting: I had no idea it was this bad. Im so sorry (Mary) that I never reached out to you when I saw you struggling. I made excuses to myself as to why I should mind my own business. We let you down. I will never turn my head again.

Cain responded to Flanagan by posting: I cant express how much this meant to me. It was scary to feel so forgotten by a community I devoted my life to. But together we can change things. As athletes, its easy to hand our agency to others, but new coaches can change the system.

At the end of her seven-minute video, Cain said: I genuinely do have hope for the sport and I plan to be running for many years to come. Part of the reasons why Im doing this now is I want to end this chapter and I want to start a new one.

Read the original here:
Nike will look into runner Mary Cain's allegations of abuse - The Associated Press

Nov 13

Sex file: Hard to have sex when you dont feel sexy – Irish Examiner

My husband has put on a lot of weight. I still fancy him, but hes become much less keen on sex. Were in our fifties and he says that its just age thats slowed his libido down. He must feel less sexy, but Im fed up that he wont make any effort to save our sex life.

Although your husband blames his age for his lack of libido, his weight is more likely to be responsible. The issue may be metabolic obesity has a negative impact on testosterone levels but stigma and low self-esteem are equally likely to cause sexual difficulties. Body image is a subjective psychological phenomenon, in that people who are a perfectly normal weight can convince themselves that they are fat, but people who are obese experience much higher levels of body dissatisfaction. It is hard to have sex when you dont feel sexy.

Despite the fact that it clearly does not work, blame and shame are routinely used to try to motivate obese individuals to lose weight.

The discrimination obese people endure is so profound that in her 2015 study Angelina R Sutin found that it was associated with an increased mortality risk of nearly 60%. She concluded that the stigma associated with being overweight or obese shortens life to such an extent that it may be more harmful than actually being overweight or obese.

There is such an intense focus on the health implications of obesity that the psychological, sexual and relational consequences are often forgotten, but many obese people experience some form of sexual dysfunction. Dealing with a triple whammy of obesity, sexual dysfunction and low self-esteem is not easy and although it feels as if your husband is rejecting you, he is actually protecting himself. After all, if he doesnt try to have sex, he avoids the possibility of sexual failure. It is not a sustainable strategy, but nagging him wont help. People dont actively choose to be obese.

It is worth reminding your husband that everyones metabolism slows by 5% each decade, so we all burn about 200 fewer calories a day at age 45 than we did at age 25. Most people also eat about 200 calories more food energy a day than they did 10 years ago, so anyone who doesnt actively fight the flab can put on significant weight.

Because it is much easier to get a fat person fit than it is to get a fat person thin, encouraging your husband to be more active and helping him to make healthier food and drink choices will have a more immediate impact than a diet. Gentle exercise will also boost his serotonin levels and that will help him to feel happier and more positive.

Getting your sex life back on track is important, but he may need help, so he needs to book an appointment with his doctor. His GP will check his heart and his testosterone levels. If they are fine he could get a prescription for Viagra, Cialis or Levitra. The drugs have different active ingredients, but the main difference between them is how long they work for.

Viagra and Levitra give the possibility of an erection for four hours, whereas with Cialis it is 36. Viagra and Cialis have not, to my knowledge, been tested on obese men, but an independent pilot study by Antonio Aversa, which was published in the International Journal of Impotence Research in 2012, evaluated the effects of Levitra on sexual distress in men with obesity. The study found that Levitra improved sexual function and had a positive impact on the participants sexual relationships, so it is probably worth a try.

Send your queries to

Excerpt from:
Sex file: Hard to have sex when you dont feel sexy - Irish Examiner

Nov 11

What is Testosterone and Why is it Important? – News Anyway

Post Views: 227

Testosterone is a hormone that is produced by your body. It has traditionally been thought of as the male sex-hormone, however, women also need testosterone, admittedly lower levels, but it is nonetheless important in both sexes. Hormones are chemical messengers that signal target organs to help them function properly.

In men, testosterone is predominantly produced by the testes, it is produced in response to signalling from the pituitary gland. Testosterone is broken down in part by the aromatase enzyme located in the testes, brain, skin, bone and liver is there is dysfunction. This enzyme converts testosterone to oestradiol. This has a negative feedback on the Hypothalamus and Pituitary gland (HPG) which forms part of the Hypo-pituitary Gland axis that controls production of testosterone.

Oestrogen has a negative feedback on the brain, suppressing the release of Lutenising Hormone (LH) from the pituitary gland, preventing stimulation of the Leydig cells of the testes and subsequent production of testosterone by these cells.

Testosterone is also broken down in part to Dihydrotestosterone (DHT) by the enzyme 5-alpha reductase located in the testes and prostate. This hormone is responsible for sexual differentiation, secondary sexual body hair, libido, muscle growth, prostate health.

Testosterone has long been thought of as simply the male sex-hormone, its role and function within the body is of far more significance. It is integral for long term physical and psychological health. In fact, its relationship and role in facilitating function is far more complex. The ratio of free testosterone to oestradiol to dihydrotestosterone is of greater significance than absolute numbers of the individual hormones.

Testosterone, Oestradiol and Dihydrotestosterone affect the following organs

As you can see, testosterone, oestrogen and dihydrotestosterone have important roles within the human body. Testosterone, oestradiol and dihydrotestosterone are anabolic hormones, their primary role is to help facilitate growth and repair. Testosterone is primarily produced at night, whilst asleep, hence levels being highest early morning. However, these hormones are necessary 24 hours a day to help support the body and combat the effects of catabolic processes that predominate when active.

All hormones are dependent, whether that be a direct relationship like the thyroid and HPG axis or indirect, they are not independent. The body likes stability, the body likes hormonal balance. There are complex physiological mechanisms maintaining a constant internal environment despite external changes. Help your body achieve homeostasis, hormonal balance is necessary for health. Testosterone, Oestradiol and Dihydrotestosterone are just as important as every other hormone involved in keeping your body healthy, time to take a stand.

Testosterone Deficiency & Diagnosis

Dr Robert Stevens MBChB MRCGP Dip.FIPT

See the original post:
What is Testosterone and Why is it Important? - News Anyway

Page 87«..1020..86878889..100..»

matomo tracker